Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs

Author(s): Jin Bo Su*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 40 , 2017


Become EABM
Become Reviewer
Call for Editor

Abstract:

NO produced by eNOS plays important roles in the cardiovascular system. Alterations in eNOS activity and expression occur in various cardiovascular disorders and eNOS constitutes a therapeutic target. In addition to posttranslational modifications of eNOS that affect eNOS activity, transcriptional and post-transcriptional regulation of eNOS expression also controls eNOS-derived NO production. Bradykinin is an important determinant of vascular function and participates in the regulation of eNOS activity and expression. A number of currently used drugs or investigational molecules targeting specific ion channels, enzymes or receptors, including dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, AT1 receptor blockers and angiotensin-(1-7), increase eNOS expression and activity. In this context, activation of bradykinin B2 receptors appears to be a common step for these drugs to promote eNOS expression, which certainly contributes to their therapeutic actions.

Keywords: Angiotensin-converting enzyme inhibitors, angiotensin-(1-7), AT1 receptor blockers, bradykinin, dihydropyridine calcium channel blockers, statins, endothelial nitric oxide synthase, nitric oxide, transcriptional and posttranscriptional regulation.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 23
ISSUE: 40
Year: 2017
Published on: 15 February, 2018
Page: [6215 - 6222]
Pages: 8
DOI: 10.2174/1381612823666170622112253
Price: $65

Article Metrics

PDF: 25
HTML: 6
EPUB: 1
PRC: 2